|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kurman RJ and IeM Shih: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kroeger PT Jr and Drapkin R: Pathogenesis
and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol.
29:26–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saijo N: Present status and problems on
molecular targeted therapy of cancer. Cancer Res Treat. 44:1–10.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thompson N, Adams DJ and Ranzani M:
Synthetic lethality: Emerging targets and opportunities in
melanoma. Pigment Cell Melanoma Res. 30:183–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duan P, Fan L, Gao Q, Silwal BM, Ren M,
Shen Y and Qu W: Targeted Therapy of Ovarian Cancer with
Angiogenesis Inhibitors. Curr Drug Targets. 18:1171–1178. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and Antitumor Activity of Anti-PD-1 Antibody,
Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang B: Development of synthetic lethality
anticancer therapeutics. J Med Chem. 57:7859–7873. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Perets R, Wyant GA, Muto KW, Bijron JG,
Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, et al:
Transformation of the fallopian tube secretory epithelium leads to
high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer
Cell. 24:751–765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scully R: Role of BRCA gene dysfunction in
breast and ovarian cancer predisposition. Breast Cancer Res.
2:324–330. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Turner N, Tutt A and Ashworth A: Hallmarks
of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dominguez-Sola D and Gautier J: MYC and
the control of DNA replication. Cold Spring Harb Perspect Med.
4:pii: a014423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kobayashi H, Shigetomi H and Yoshimoto C:
Checkpoint kinase 1 inhibitors as targeted molecular agents for
clear cell carcinoma of the ovary. Oncol Lett. 10:571–576. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lyttle B, Bernardi L and Pavone ME:
Ovarian cancer in endometriosis: Clinical and molecular aspects.
Minerva Ginecol. 66:155–164. 2014.PubMed/NCBI
|
|
15
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin Y, Li Y and Pan L: The target therapy
of ovarian clear cell carcinoma. OncoTargets Ther. 7:1647–1652.
2014. View Article : Google Scholar
|
|
17
|
Tsuchiya A, Sakamoto M, Yasuda J, Chuma M,
Ohta T, Ohki M, Yasugi T, Taketani Y and Hirohashi S: Expression
profiling in ovarian clear cell carcinoma: Identification of
hepatocyte nuclear factor-1 beta as a molecular marker and a
possible molecular target for therapy of ovarian clear cell
carcinoma. Am J Pathol. 163:2503–2512. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shigetomi H, Sudo T, Shimada K, Uekuri C,
Tsuji Y, Kanayama S, Naruse K, Yamada Y, Konishi N and Kobayashi H:
Inhibition of cell death and induction of G2 arrest accumulation in
human ovarian clear cells by HNF-1β transcription factor:
Chemosensitivity is regulated by checkpoint kinase CHK1. Int J
Gynecol Cancer. 24:838–843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng ZG, Yao YB, Yang J, Tang YL and Huang
X: Mangiferin induces cell cycle arrest at G2/M phase through
ATR-Chk1 pathway in HL-60 leukemia cells. Genet Mol Res.
14:4989–5002. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ito F, Yoshimoto C, Yamada Y, Sudo T and
Kobayashi H: The HNF-1β-USP28-Claspin pathway upregulates DNA
damage-induced Chk1 activation in ovarian clear cell carcinoma.
Oncotarget. 9:17512–17522. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kobayashi H, Sugimoto H, Onishi S and
Nakano K: Novel biomarker candidates for the diagnosis of ovarian
clear cell carcinoma. Oncol Lett. 10:612–618. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Itamochi H, Nishimura M, Oumi N, Kato M,
Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Kudoh A, et al:
Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance
in clear cell carcinoma of the ovary. Int J Gynecol Cancer.
24:61–69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang S, Wu L, Li X, Huang J, Zhong J and
Chen X: Crizotinib-associated toxic epidermal necrolysis in an
ALK-positive advanced NSCLC patient. Mol Clin Oncol. 8:457–459.
2018.PubMed/NCBI
|
|
24
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM,
Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I,
et al ENGOT-OV16/NOVA Investigators: Niraparib Maintenance Therapy
in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med.
375:2154–2164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Papa A, Caruso D, Strudel M, Tomao S and
Tomao F: Update on Poly-ADP-ribose polymerase inhibition for
ovarian cancer treatment. J Transl Med. 14:2672016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Raj L, Ide T, Gurkar AU, Foley M, Schenone
M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al:
Selective killing of cancer cells by a small molecule targeting the
stress response to ROS. Nature. 475:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo J, Liu H and Zheng J: SynLethDB:
Synthetic lethality database toward discovery of selective and
sensitive anticancer drug targets. Nucleic Acids Res. 44(D1):
D1011–D1017. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pathak HB, Zhou Y, Sethi G, Hirst J,
Schilder RJ, Golemis EA and Godwin AK: A Synthetic Lethality Screen
Using a Focused siRNA Library to Identify Sensitizers to Dasatinib
Therapy for the Treatment of Epithelial Ovarian Cancer. PLoS One.
10:e01441262015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Crespan E, Garbelli A, Amoroso A and Maga
G: Exploiting the nucleotide substrate specificity of repair DNA
polymerases to develop novel anticancer agents. Molecules.
16:7994–8019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bitler BG, Fatkhutdinov N and Zhang R:
Potential therapeutic targets in ARID1A-mutated cancers. Expert
Opin Ther Targets. 19:1419–1422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Williamson CT, Miller R, Pemberton HN,
Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati
A, et al: ATR inhibitors as a synthetic lethal therapy for tumours
deficient in ARID1A. Nat Commun. 7:138372016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jdey W, Thierry S, Russo C, Devun F, Al
Abo M, Noguiez-Hellin P, Sun JS, Barillot E, Zinovyev A, Kuperstein
I, et al: Drug-Driven Synthetic Lethality: Bypassing Tumor Cell
Genetics with a Combination of AsiDNA and PARP Inhibitors. Clin
Cancer Res. 23:1001–1011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Toledo LI, Murga M, Zur R, Soria R,
Rodriguez A, Martinez S, Oyarzabal J, Pastor J, Bischoff JR and
Fernandez-Capetillo O: A cell-based screen identifies ATR
inhibitors with synthetic lethal properties for cancer-associated
mutations. Nat Struct Mol Biol. 18:721–727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Subhash VV, Tan SH, Yeo MS, Yan FL,
Peethala PC, Liem N, Krishnan V and Yong WP: ATM Expression
Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by
Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.
Mol Cancer Ther. 15:3087–3096. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang X, Zhang Y, Han ZG and He KY:
Malignancy of Cancers and Synthetic Lethal Interactions Associated
With Mutations of Cancer Driver Genes. Medicine (Baltimore).
95:e26972016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carvalho JF and Kanaar R: Targeting
homologous recombination-mediated DNA repair in cancer. Expert Opin
Ther Targets. 18:427–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu FW and Tewari KS: New Targeted Agents
in Gynecologic Cancers: Synthetic Lethality, Homologous
Recombination Deficiency, and PARP Inhibitors. Curr Treat Options
Oncol. 17:122016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH,
Lee JE, Wang C, Brindle PK, Dent SY and Ge K: Distinct roles of
GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in
nuclear receptor transactivation. EMBO J. 30:249–262. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ogiwara H, Sasaki M, Mitachi T, Oike T,
Higuchi S, Tominaga Y and Kohno T: Targeting p300 Addiction in
CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell
Death due to Abrogation of MYC Expression. Cancer Discov.
6:430–445. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hoffman GR, Rahal R, Buxton F, Xiang K,
McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D,
et al: Functional epigenetics approach identifies BRM/SMARCA2 as a
critical synthetic lethal target in BRG1-deficient cancers. Proc
Natl Acad Sci USA. 111:3128–3133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Raab JR, Runge JS, Spear CC and Magnuson
T: Co-regulation of transcription by BRG1 and BRM, two mutually
exclusive SWI/SNF ATPase subunits. Epigenetics Chromatin.
10:622017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chandramouly G, McDevitt S, Sullivan K,
Kent T, Luz A, Glickman JF, Andrake M, Skorski T and Pomerantz RT:
Small-Molecule Disruption of RAD52 Rings as a Mechanism for
Precision Medicine in BRCA-Deficient Cancers. Chem Biol.
22:1491–1504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wiegmans AP, Yap PY, Ward A, Lim YC and
Khanna KK: Differences in Expression of Key DNA Damage Repair Genes
after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with
PARP1 Inhibition. Mol Cancer Ther. 14:2321–2331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gatei M, Kijas AW, Biard D, Dörk T and
Lavin MF: RAD50 phosphorylation promotes ATR downstream signaling
and DNA restart following replication stress. Hum Mol Genet.
23:4232–4248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sanjiv K, Hagenkort A, Calderón-Montaño
JM, Koolmeister T, Reaper PM, Mortusewicz O, Jacques SA, Kuiper RV,
Schultz N, Scobie M, et al: Cancer-Specific Synthetic Lethality
between ATR and CHK1 Kinase Activities. Cell Reports. 14:298–309.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lamba S, Russo M, Sun C, Lazzari L,
Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio
F and Bardelli A: RAF suppression synergizes with MEK inhibition in
KRAS mutant cancer cells. Cell Reports. 8:1475–1483. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Morgan RD, Clamp AR, Evans DGR, Edmondson
RJ and Jayson GC: PARP inhibitors in platinum-sensitive high-grade
serous ovarian cancer. Cancer Chemother Pharmacol. 81:647–658.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Arakawa N, Kobayashi H, Yonemoto N,
Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y,
Hirahara F, et al: Clinical Significance of Tissue Factor Pathway
Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell
Carcinoma. PLoS One. 11:e01656092016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Y, Helland A, Holm R, Kristensen GB
and Børresen-Dale AL: PIK3CA mutations in advanced ovarian
carcinomas. Hum Mutat. 25:3222005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki
S, Kakuda M, Okazawa A, Egawa-Takata T, Kobayashi E and Kimura T:
Potential targets for ovarian clear cell carcinoma: A review of
updates and future perspectives. Cancer Cell Int. 15:1172015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fokas E, Prevo R, Pollard JR, Reaper PM,
Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM,
Gillies McKenna W, et al: Targeting ATR in vivo using the novel
inhibitor VE-822 results in selective sensitization of pancreatic
tumors to radiation. Cell Death Dis. 3:e4412012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lee JM, Nair J, Zimmer A, Lipkowitz S,
Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee
MJ, et al: Prexasertib, a cell cycle checkpoint kinase 1 and 2
inhibitor, in BRCA wild-type recurrent high-grade serous ovarian
cancer: A first-in-class proof-of-concept phase 2 study. Lancet
Oncol. 19:207–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
McCabe N, Hanna C, Walker SM, Gonda D, Li
J, Wikstrom K, Savage KI, Butterworth KT, Chen C, Harkin DP, et al:
Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with
Inhibitors of the DNA Damage Response Kinase ATM. Cancer Res.
75:2159–2165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dedes KJ, Wetterskog D, Mendes-Pereira AM,
Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A,
Lord CJ, et al: PTEN deficiency in endometrioid endometrial
adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl
Med. 2:53ra75. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Basith S, Cui M, Macalino SJY and Choi S:
Expediting the Design, Discovery and Development of Anticancer
Drugs using Computational Approaches. Curr Med Chem. 24:4753–4778.
2017.PubMed/NCBI
|
